Literature DB >> 28000148

Regadenoson-induced complete heart block and asystole: A real possibility nuclear laboratories should be aware of.

Faraz Kureshi1,2, Mouin S Abdallah3, Timothy M Bateman4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28000148     DOI： 10.1007/s12350-016-0755-1

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  17 in total

1.  Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

Authors:  Toufigh Gordi; Brent Blackburn; Hsiao Lieu
Journal:  J Clin Pharmacol       Date:  2007-07       Impact factor: 3.126

2.  Recommendations for clinical exercise laboratories: a scientific statement from the american heart association.

Authors:  Jonathan Myers; Ross Arena; Barry Franklin; Ileana Pina; William E Kraus; Kyle McInnis; Gary J Balady
Journal:  Circulation       Date:  2009-06-01       Impact factor: 29.690

3.  Complete heart block associated with regadenoson: a real side effect.

Authors:  Anil Pandit; Samuel Unzek Freiman
Journal:  J Nucl Cardiol       Date:  2012-08-23       Impact factor: 5.952

4.  ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures.

Authors:  Vasken Dilsizian; Stephen L Bacharach; Rob S Beanlands; Steven R Bergmann; Dominique Delbeke; Sharmila Dorbala; Robert J Gropler; Juhani Knuuti; Heinrich R Schelbert; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2016-07-08       Impact factor: 5.952

5.  Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

Authors:  Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

6.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

Review 7.  Regadenoson: a new myocardial stress agent.

Authors:  Wael Al Jaroudi; Ami E Iskandrian
Journal:  J Am Coll Cardiol       Date:  2009-09-22       Impact factor: 24.094

8.  Asystole following regadenoson infusion in stable outpatients.

Authors:  Jeffrey Rosenblatt; Deirdre Mooney; Timothy Dunn; Mylan Cohen
Journal:  J Nucl Cardiol       Date:  2014-05-31       Impact factor: 5.952

9.  Regadenoson.

Authors:  Karly P Garnock-Jones; Monique P Curran
Journal:  Am J Cardiovasc Drugs       Date:  2010       Impact factor: 3.571

10.  A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.

Authors:  Bruce M Prenner; Stan Bukofzer; Sarah Behm; Kathleen Feaheny; Bruce E McNutt
Journal:  J Nucl Cardiol       Date:  2012-04-07       Impact factor: 5.952
View more
  2 in total

1.  Relationship of 82Rb PET territorial myocardial asynchrony to arterial stenosis.

Authors:  Andrew Van Tosh; John R Votaw; C David Cooke; J Jane Cao; Christopher J Palestro; Kenneth J Nichols
Journal:  J Nucl Cardiol       Date:  2018-06-26       Impact factor: 5.952

2.  Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.

Authors:  Efstathia Andrikopoulou; Charity J Morgan; Lizbeth Brice; Navkaranbir S Bajaj; Harish Doppalapudi; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-10-17       Impact factor: 5.952
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.